Friday 18th August 2023 update: login access to this repository is currently paused pending an upgrade to a new DSpace version in September 2023. If you have a query about submitting to this repository please contact the library repository administrators via the 'Contact Us' link in at the bottom of this page. FAO repository administrators: please do not add new items to the repository in this time and contact Atmire if any query.

Show simple item record

dc.contributor.authorErasmus, M.
dc.contributor.authorSamodien, E.
dc.contributor.authorLecour, S.
dc.contributor.authorCour, M.
dc.contributor.authorLorenzo, O.
dc.contributor.authorDludla, P.
dc.contributor.authorPheiffer, C.
dc.contributor.authorJohnson, R.
dc.identifier.citationErasmus M, Samodien E, Lecour S, Cour M, et al. Linking LOXL2 to Cardiac Interstitial Fibrosis. Int J Mol Sci. 2020 Aug 18;21(16):5913.doi:10.3390/ijms21165913.en_US
dc.description.abstractCardiovascular diseases (CVDs) are the leading causes of death worldwide. CVD pathophysiology is often characterized by increased stiffening of the heart muscle due to fibrosis, thus resulting in diminished cardiac function. Fibrosis can be caused by increased oxidative stress and inflammation, which is strongly linked to lifestyle and environmental factors such as diet, smoking, hyperglycemia, and hypertension. These factors can affect gene expression through epigenetic modifications. Lysyl oxidase like 2 (LOXL2) is responsible for collagen and elastin cross-linking in the heart, and its dysregulation has been pathologically associated with increased fibrosis. Additionally, studies have shown that, LOXL2 expression can be regulated by DNA methylation and histone modification. However, there is a paucity of data on LOXL2 regulation and its role in CVD. As such, this review aims to gain insight into the mechanisms by which LOXL2 is regulated in physiological conditions, as well as determine the downstream effectors responsible for CVD development.en_US
dc.description.sponsorshipFunding: The work reported herein was made possible through funding by the South Africa Medical Research Council’sBiomedicalResearchandInnovationPlatformbaselinefundingaswellasDivisionofResearchCapacity DevelopmentInternshipScholarshipandIntra-muralPost-DoctoralScholarshipProgram. As well as the National Research Foundation (NRF)ThuthukaProgramme107261,theCompetitiveprogramforRatedResearchers(CPRR) 120812,theNRF,ProfessionalDevelopmentProgramme(PDP)grant104912,NRFgrant117829,theNRFExtension grant12098,andtheSouthAfricanRooibosCouncilgrant. In addition, The NRF echocardiograph large equipment Grant at the University of Cape Town.en_US
dc.rightsAttribution 3.0 United States*
dc.subjectDNA methylationen_US
dc.subjectLysyl Oxidase-Like 2 (LOXL2)en_US
dc.subjectCardiovascular disease (CVD)en_US
dc.titleLinking LOXL2 to cardiac interstitial fibrosisen_US
dc.contributor.departmentBiomedical Research and Innovation Platform, South African Medical Research Councilen_US
dc.identifier.journalInternational Journal of Molecular Sciencesen_US
dc.research.unitBiomedical Research and Innovation Platformen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution 3.0 United States
Except where otherwise noted, this item's license is described as Attribution 3.0 United States